Dynamic Healthcare M&A Database

Acquiring Party	Alcon (ACL), a $6.19b manufacturer of surgical equipment, implantable lenses, and other eye care products.
Transferring Party	Optonol, Ltd., an Israel-based manufacturer of miniature surgical implants for glaucoma.
Sector	Medical Devices
Date	December 14, 2009
Analysis Optonol's implants are used to lower intraocular pressure (IOP) in glaucoma patients. The deal complements Alcon’s pharmaceutical products that lower IOP in patients with glaucoma and ocular hypertension. The implants have benefits over trabeculectomy, now considered the standard of care in glaucoma surgical therapy. When glaucoma damages the optic nerve, subtle loss of vision begins in the peripheral vision and can progress to loss of central vision and blindness. Glaucoma has no signs or symptoms and sufferers usually do not notice the disease until significant vision loss has occurred. Terms not disclosed.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 4Q09